Alan R Flesher

Title: Alan R. Flesher: A Pioneer in Recombinant Protein Production

Introduction

Alan R. Flesher, based in Lawrenceville, NJ, has made significant contributions to the field of biopharmaceuticals through his inventive works. With a total of five patents to his name, Flesher's innovations have advanced the methods of producing critical therapeutic proteins, particularly CTLA4-Ig.

Latest Patents

Alan R. Flesher's most recent patents focus on groundbreaking compositions and methods for producing a specific protein known as CTLA4-Ig. His inventions describe mammalian cells engineered to produce recombinant CTLA4-Ig and its variants. The patents also cover compositions that utilize CTLA4-Ig, along with various formulations, and outline effective methods for mass-producing and purifying this recombinant protein from mammalian cells.

Career Highlights

Alan Flesher is currently associated with Bristol-Myers Squibb Company, a leading global biopharmaceutical firm. His work at Bristol-Myers Squibb has allowed him to engage deeply in research and development, focusing on the production of essential therapeutic proteins that have wide applications in treating various diseases.

Collaborations

Throughout his career, Alan has collaborated with notable colleagues, including Kirk J. Leister and Eugene J. Schaefer. These partnerships have facilitated innovative research efforts, further enhancing the impact of his work in the biopharmaceutical field.

Conclusion

In summary, Alan R. Flesher's contributions to the field of biotechnology and biopharmaceuticals are commendable. His patents reflect a commitment to improving the mass production and purification of therapeutic proteins, which have the potential to provide significant benefits to patient care. As he continues to work at Bristol-Myers Squibb, the future of his innovative endeavors looks bright.